Comparison of Aflibercept (Eylea®) with Ranibizumab (Lucentis®) in treatment of diabetic macular edema by Optical Coherence Tomography
Background: Diabetic macular edema (DME) can occur at any stage of non-proliferative and proliferative diabetic retinopathy. It is characterized by a swelling of the macular area that normally accounts for high-resolution visual acuity (VA), and DME therefore leads to visual deterioration. Objective...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Beni-Suef University, Faculty of Medicine
2022-04-01
|
| Series: | Egyptian Journal of Medical Research |
| Subjects: | |
| Online Access: | https://ejmr.journals.ekb.eg/article_240903_0a2753be9a04b656e6d6b935081ac6fa.pdf |
| _version_ | 1797893977158975488 |
|---|---|
| author | Hossam El din Khalil Abdel Rahman Ahmed Hassan Mahfouz Eliwa |
| author_facet | Hossam El din Khalil Abdel Rahman Ahmed Hassan Mahfouz Eliwa |
| author_sort | Hossam El din Khalil |
| collection | DOAJ |
| description | Background: Diabetic macular edema (DME) can occur at any stage of non-proliferative and proliferative diabetic retinopathy. It is characterized by a swelling of the macular area that normally accounts for high-resolution visual acuity (VA), and DME therefore leads to visual deterioration.
Objective: To compare the effect of Aflibercept (Eylea®) with Ranibizumab (Lucentis®) in treatment of diabetic macular edema by OCT. Patients and Methods: This was a prospective comparative study conducted on 32 Diabetic macular edema (DME); to compare the effect of Aflibercept (Eylea®) with Ranibizumab (Lucentis®) in treatment of diabetic macular edema by OCT. Results: Pre-operative BCVA had a highly significant positive correlation with post-operative BCVA (p < 0.0001). DM duration had a highly significant negative correlation with post-operative BCVA (p = 0.0002). Logistic regression analysis shows that; after applying (Forward method) and entering some predictor variables; the decrease in DM duration; had an independent effect on increasing the probability of patient’s visual acuity improvement; with significant statistical difference (p = 0.042). By using ROC-curve analysis, Aflibercept and Ranibizumab usage showed non-significant predictive values in discrimination of improved patients from patients worsened ones (p > 0.05). Conclusion: Both aflibercept and ranibizumab improve visual acuity and decrease CMT in eyes with DME and moderate visual loss with no difference between the two drugs. |
| first_indexed | 2024-04-10T07:01:28Z |
| format | Article |
| id | doaj.art-333739977afa48f68fa29a9989fa22cf |
| institution | Directory Open Access Journal |
| issn | 2682-4396 2682-440X |
| language | English |
| last_indexed | 2024-04-10T07:01:28Z |
| publishDate | 2022-04-01 |
| publisher | Beni-Suef University, Faculty of Medicine |
| record_format | Article |
| series | Egyptian Journal of Medical Research |
| spelling | doaj.art-333739977afa48f68fa29a9989fa22cf2023-02-27T17:41:48ZengBeni-Suef University, Faculty of MedicineEgyptian Journal of Medical Research2682-43962682-440X2022-04-013222624210.21608/ejmr.2022.240903240903Comparison of Aflibercept (Eylea®) with Ranibizumab (Lucentis®) in treatment of diabetic macular edema by Optical Coherence TomographyHossam El din Khalil0Abdel Rahman Ahmed1Hassan Mahfouz Eliwa2Department of Ophthalmology, Faculty of Medicine, Beni-Suef UniversityDepartment of Ophthalmology, Faculty of Medicine, Beni-Suef UniversityDepartment of Ophthalmology, Faculty of Medicine, Beni-Suef UniversityBackground: Diabetic macular edema (DME) can occur at any stage of non-proliferative and proliferative diabetic retinopathy. It is characterized by a swelling of the macular area that normally accounts for high-resolution visual acuity (VA), and DME therefore leads to visual deterioration. Objective: To compare the effect of Aflibercept (Eylea®) with Ranibizumab (Lucentis®) in treatment of diabetic macular edema by OCT. Patients and Methods: This was a prospective comparative study conducted on 32 Diabetic macular edema (DME); to compare the effect of Aflibercept (Eylea®) with Ranibizumab (Lucentis®) in treatment of diabetic macular edema by OCT. Results: Pre-operative BCVA had a highly significant positive correlation with post-operative BCVA (p < 0.0001). DM duration had a highly significant negative correlation with post-operative BCVA (p = 0.0002). Logistic regression analysis shows that; after applying (Forward method) and entering some predictor variables; the decrease in DM duration; had an independent effect on increasing the probability of patient’s visual acuity improvement; with significant statistical difference (p = 0.042). By using ROC-curve analysis, Aflibercept and Ranibizumab usage showed non-significant predictive values in discrimination of improved patients from patients worsened ones (p > 0.05). Conclusion: Both aflibercept and ranibizumab improve visual acuity and decrease CMT in eyes with DME and moderate visual loss with no difference between the two drugs.https://ejmr.journals.ekb.eg/article_240903_0a2753be9a04b656e6d6b935081ac6fa.pdfdiabetic macular edemavisual acuity |
| spellingShingle | Hossam El din Khalil Abdel Rahman Ahmed Hassan Mahfouz Eliwa Comparison of Aflibercept (Eylea®) with Ranibizumab (Lucentis®) in treatment of diabetic macular edema by Optical Coherence Tomography Egyptian Journal of Medical Research diabetic macular edema visual acuity |
| title | Comparison of Aflibercept (Eylea®) with Ranibizumab (Lucentis®) in treatment of diabetic macular edema by Optical Coherence Tomography |
| title_full | Comparison of Aflibercept (Eylea®) with Ranibizumab (Lucentis®) in treatment of diabetic macular edema by Optical Coherence Tomography |
| title_fullStr | Comparison of Aflibercept (Eylea®) with Ranibizumab (Lucentis®) in treatment of diabetic macular edema by Optical Coherence Tomography |
| title_full_unstemmed | Comparison of Aflibercept (Eylea®) with Ranibizumab (Lucentis®) in treatment of diabetic macular edema by Optical Coherence Tomography |
| title_short | Comparison of Aflibercept (Eylea®) with Ranibizumab (Lucentis®) in treatment of diabetic macular edema by Optical Coherence Tomography |
| title_sort | comparison of aflibercept eylea r with ranibizumab lucentis r in treatment of diabetic macular edema by optical coherence tomography |
| topic | diabetic macular edema visual acuity |
| url | https://ejmr.journals.ekb.eg/article_240903_0a2753be9a04b656e6d6b935081ac6fa.pdf |
| work_keys_str_mv | AT hossameldinkhalil comparisonofaflibercepteyleawithranibizumablucentisintreatmentofdiabeticmacularedemabyopticalcoherencetomography AT abdelrahmanahmed comparisonofaflibercepteyleawithranibizumablucentisintreatmentofdiabeticmacularedemabyopticalcoherencetomography AT hassanmahfouzeliwa comparisonofaflibercepteyleawithranibizumablucentisintreatmentofdiabeticmacularedemabyopticalcoherencetomography |